Profile data is unavailable for this security.
About the company
Worldwide Healthcare Trust PLC is a specialist investment trust. The Company invests in the global healthcare sector with the objective of achieving a high level of capital growth. It invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It invests up to 10% of the portfolio, at the time of acquisition, in unquoted securities. It invests approximately 50% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. It may invest over 5% of the portfolio, at the time of acquisition, in debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over 30% of the portfolio in companies under sectors, such as healthcare equipment and supplies, and healthcare providers and services. Its alternative investment fund manager is Frostrow Capital LLP. OrbiMed Capital LLC is its portfolio manager.
- Revenue in GBP (TTM)253.44m
- Net income in GBP227.52m
- Incorporated1995
- Employees0.00
- LocationWorldwide HealthcareFrostrow Capital LLP25 Southampton BuildingsLONDON WC2A 1ALUnited KingdomGBR
- Phone+44 20 3008 4910
- Websitehttps://www.worldwidewh.com/
Profile
| Management group(s) | Frostrow Capital LLP |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GB00BN455J50 |
| Launch date | 28 Apr 1995 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
In order to achieve a high level of capital growth, the Company invests in the global healthcare sector and in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to mitigate risk and also to enhance returns.
Managed by
| Sven H. Borho, Trevor M. Polischuk |
|---|
Management & contract fees
The Investment Manager receives a fee equal to 0.65% p.a. of the NAV of Company. The performance fee amounts to 15% of any outperformance of the NAV over the benchmark index. The Company may be terminated by either party giving notice of not less than 12 months.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Finsbury Growth & Income Trust PLC | 16.81m | 2.34m |
| Fidelity European Trust PLC | 234.02m | 207.26m |
| BH Macro Ltd | 152.21m | 35.60m |
| Pantheon International PLC | 78.93m | 31.65m |
| Allianz Technology Trust PLC | 521.55m | 511.54m |
| Rathbones Group PLC | 888.53m | 63.32m |
| Murray International Trust plc | 204.49m | 184.74m |
| Personal Assets Trust PLC | 66.67m | 44.26m |
| JTC PLC | 283.06m | 29.13m |
| Worldwide Healthcare Trust PLC | 253.44m | 227.52m |
| Templeton Emerging Markets Inv Trust plc | 172.27m | 140.33m |
| Mercantile Investment Trust PLC | 435.03m | 411.79m |
| HarbourVest Global Private Equity Ltd | 108.29m | 76.97m |
| Caledonia Investments plc | 233.80m | 203.80m |
| AJ Bell PLC | 245.88m | 81.33m |
| Smithson Investment Trust PLC | -26.10m | -51.47m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 31 Mar 2024 | 48.44m | 9.07% |
| Investec Wealth & Investment Ltd.as of 31 Mar 2024 | 42.23m | 7.91% |
| Hargreaves Lansdown Asset Management Ltd.as of 31 Mar 2024 | 32.44m | 6.08% |
| Forsyth Barr Ltd.as of 31 Mar 2024 | 21.38m | 4.00% |
| Craigs Investment Partners Ltd. (Investment Management)as of 31 Mar 2024 | 19.67m | 3.69% |
| Evelyn Partners Investment Management LLPas of 31 Mar 2024 | 19.45m | 3.64% |
| Quilter Cheviot Ltd.as of 31 Mar 2024 | 18.65m | 3.49% |
| Brewin Dolphin Ltd.as of 31 Mar 2024 | 18.50m | 3.47% |
| Close Asset Management Ltd.as of 01 Oct 2024 | 13.24m | 2.48% |
| Vanguard Global Advisers LLCas of 31 Oct 2024 | 7.75m | 1.45% |
